



ETOPOSIDE oral - local funding required

INDICATION (ICD10) C41, C49

1. Palliative sarcoma. PS 0, 1, 2

REGIMEN

Days 1 to 21 ETOPOSIDE 50mg/m² orally once daily

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 28 days until disease progression

ADMINISTRATION

Available as 50mg and 100mg capsules Take on an empty stomach

ANTI-EMETICS

Low emetic risk days 1 to 21

CONCURRENT MEDICATION REQUIRED

Etoposide	None required

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x 10⁹/L ≥1.5

Platelets x 10⁹/L ≥100

Creatinine clearance (GFR) calculated, at the Consultants discretion

Serum creatinine - each cycle,

Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Etoposide	-	

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

Etoposide	Ciclosporin
	Warfarin check INR, st johns wort, phenytoin

DOSE MODIFICATIONS

Haematological

ANC and platelet counts (109/L)	Current etoposide cycle	Subsequent etoposide cycle
ANC >0.5 and platelets >50	Continue with current etoposide cycle	Continue 100%
ANC <0.5 and/or platelets <50	Stop current etoposide cycle	Give 75% dose in subsequent cycle on count recovery

Hepatic impairment

Etoposide

Bilirubin >50micromol/L or decreased albumin	give 50% dose





Renal impairment

Etoposide

CrCl >50ml/min	give 100% dose
CrCl 15-50ml/min	give 75% dose
CrCl <15ml/min	further dose reduction

REFERENCES

- 1. Etoposide SPC; http://www.medicines.org.uk/emc/medicine/7051
- 2. 2 Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatric blood & cancer. 2004;42(4):320-4.
- 3. Davidson A, Lewis I, Pearson ADJ, et al. 21-Day Schedule oral etoposide in children a Feasibility Study. Eur J Cancer 1993